Biologic Drugs With Mechanism of Action: Lymphocyte Activation Gene-3 Antagonists
✉ Email this page to a colleague
Biologic Drugs With Mechanism of Action: Lymphocyte Activation Gene-3 Antagonists
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bristol-myers Squibb Company | OPDUALAG | nivolumab and relatlimab-rmbw | Injection | 761234 | 2022-03-18 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |